UniProt Q13177 · PDB · AlphaFold · Substrate: PAKtide · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Neratinib | 87.7% | 12.3% | 93.18 | 0.597 |
| 2 | Fostamatinib | 33.4% | 66.6% | 96.74 | 0.613 |
| 3 | Defactinib | 29.9% | 70.1% | 92.68 | 0.450 |
| 4 | Bosutinib | 29.6% | 70.4% | 87.22 | 0.555 |
| 5 | Vemurafenib | 29.4% | 70.6% | 96.49 | 0.598 |
| 6 | Midostaurin | 24.3% | 75.7% | 78.64 | 0.500 |
| 7 | Pacritinib | 21.4% | 78.6% | 88.64 | 0.452 |
| 8 | Pralsetinib | 15.6% | 84.4% | 93.43 | 0.643 |
| 9 | Ponatinib | 14.0% | 86.0% | 78.23 | 0.534 |
| 10 | Nilotinib | 13.1% | 86.9% | 96.49 | 0.765 |
| 11 | Ibrutinib | 12.8% | 87.2% | 94.74 | 0.723 |
| 12 | Abemaciclib | 12.6% | 87.4% | 91.48 | 0.563 |
| 13 | Pazopanib | 11.9% | 88.1% | 97.49 | 0.672 |
| 14 | Brigatinib | 11.9% | 88.1% | 82.96 | 0.513 |
| 15 | Tenalisib | 11.7% | 88.3% | 97.98 | 0.702 |
| 16 | Crizotinib | 11.2% | 88.8% | 91.39 | 0.581 |
| 17 | Ceritinib | 11.2% | 88.8% | 95.44 | 0.618 |
| 18 | Nintedanib | 10.9% | 89.1% | 90.23 | 0.608 |
| 19 | Axitinib | 10.8% | 89.2% | 93.23 | 0.688 |
| 20 | Lenvatinib | 10.3% | 89.7% | 97.74 | 0.726 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.30
- Epithelial log2(TPM+1): 5.15
- Fold change: 0.16
- Status: No significant change
Selectivity landscape vs inhibition on PAK2
Each point is one of the 92 approved drugs; color = inhibition % on PAK2.
Mutation lollipop
Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.
Variants (1)
Mutation × cancer associations
| Mutation | Cancer | Organ | Source |
|---|---|---|---|
| Y443N | Colon/Colorectal Cancer | Large Intestine | ref |
| Y443N | carcinoma_ovary | Ovary | ref |
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…